Search bioRxiv⌕ Search

Biology subjects

Connor, F.

Publications and source records attributed to Connor, F..

6 recordsLinked to original sources

Explainable machine learning relates histological to genomic pathology

Background & AimsHaematoxylin and eosin (H&E) staining remains the diagnostic gold standard for solid cancers, including hepatocellular carcinoma, and is increasingly complemented by genomic profiling for precision medicine. Inferring genomic alterations directly from H&E images could streamline testing, but heterogeneity and biases in human training data limit interpretation of genotype-phenotype associations. Here, we aimed to relate histologic to genomic pathology to provide biological explainability for mutation prediction models and assess the impact of germline variation on model performance. MethodsWe analysed 597 murine liver tumours with matched whole-genome sequencing and histopathology (163,835 image tiles; 22.9 million nuclei). Our controlled in vivo design accounted for germline variation, biological sex, and causal mutagen (N-diethylnitrosamine), removing confounding factors present in human cohorts. We trained and evaluated deep learning and supervised machine learning models to predict germline variation and cancer driver alterations from H&E. ResultsModelling accurately predicted germline and somatic alterations from histology, at both locus-specific and genome-wide scales. Quantitative image analysis revealed an unexpected association between Egfr driver mutations and hepatic steatosis, linking genotype to an interpretable morphological phenotype. While model performance declined when applied to tumours from unrepresented genetic backgrounds, this limitation was biologically informative, revealing strain-dependent differences in tumour evolution, notably the prevalence of whole-genome duplication. ConclusionsMachine learning integration of histological and genomic pathology enables accurate, interpretable inference of genetic alterations from H&E, potentially reducing reliance on costly ancillary molecular assays. Our predictions are supported by human-interpretable biological features, addressing concerns around "black-box" technologies. However, caution is required when applying such methods to samples with a genetic background that, even if closely related, is beyond the genetic horizon of training data.

pathology↗

Tissue-specific chromatin accessibility and co-factor availability together define ASCL1-dependent neural reprogrammability across germ layers during embryogenesis

The proneural transcription factor ASCL1 is well established as a pioneering neuronal reprogramming factor in several contexts. However, the extent to which distinct tissue types adopt a similar or divergent response to the same ASCL1 fate challenge is unclear. By expressing ASCL1 across germ layers and tissues of the developing Xenopus neurula embryo, we reveal widespread but largely distinct transcriptomic and chromatin responses to ASCL1. Ectopic ASCL1 can access partially open chromatin sites across all tissues, but it is able to further open those sites specifically in neuroectoderm. Using motif enrichment and accessibility analyses we identify Sox transcription factor motifs as enriched and preferentially accessible at ASCL1-bound regions in neuroectoderm. We show that co-expression of Sox3 and ASCL1 can enable the activation of otherwise refractory ASCL1 target genes in mesoderm and epidermal skin. Our findings reveal how the chromatin landscape and co-factor availability work together to modulate the response to transcription factor-driven fate challenge during development. Summary statementSingle-cell multi-omics reveals how chromatin accessibility and cofactor availability constrains ASCL1-driven neuronal reprogramming across tissues in the developing Xenopus embryo.

developmental biology↗

Genetic background sets the trajectory of cancer evolution

Human cancers are heterogeneous. Their genomes evolve from genetically diverse germlines in complex and dynamic environments, including exposure to potential carcinogens. This heterogeneity of humans, our environmental exposures, and subsequent tumours makes it challenging to understand the extent to which cancer evolution is predictable. Addressing this limitation, we re-ran early tumour evolution hundreds of times in diverse, inbred mouse strains, capturing genetic variation comparable to and beyond that found in human populations. The sex, environment, and carcinogenic exposures were all controlled and tumours comprehensively profiled with whole genome and transcriptome sequencing. Within a strain, there was a high degree of consistency in the mutational landscape, a limited range of driver mutations, and all strains converged on the acquisition of a MAPK activating mutation with similar transcriptional disruption of that pathway. Despite these similarities in the phenotypic state of tumours, different strains took markedly divergent paths to reach that state. This included pronounced biases in the precise driver mutations, the strain specific occurrence of whole genome duplication, and differences in subclonal selection that reflected both cancer susceptibility and tumour growth rate. These results show that interactions between the germline genome and the environment are highly deterministic for the trajectory of tumour genome evolution, and even modest genetic divergence can substantially alter selection pressures during cancer development, influencing both cancer risk and the biology of the tumour that develops.

genomics↗

Strand-resolved mutagenicity of DNA damage and repair

DNA base damage is a major source of oncogenic mutations1. Such damage can produce strand-phased mutation patterns and multiallelic variation through the process of lesion segregation2. Here, we exploited these properties to reveal how strand-asymmetric processes, such as replication and transcription, shape DNA damage and repair. Despite distinct mechanisms of leading and lagging strand replication3,4, we observe identical fidelity and damage tolerance for both strands. For small DNA adducts, our results support a model in which the same translesion polymerase is recruited on-the-fly to both replication strands, starkly contrasting the strand asymmetric tolerance of bulky adducts5. We find that DNA damage tolerance is also common during transcription, where RNA-polymerases frequently bypass lesions without triggering repair. At multiple genomic scales, we show the pattern of DNA damage induced mutations is largely shaped by the influence of DNA accessibility on repair efficiency, rather than gradients of DNA damage. Finally, we reveal specific genomic conditions that can corrupt the fidelity of nucleotide excision repair and actively drive oncogenic mutagenesis. These results provide insight into how strand-asymmetric mechanisms underlie the formation, tolerance, and repair of DNA damage, thereby shaping cancer genome evolution.

genomics↗

Pervasive lesion segregation shapes cancer genome evolution

Cancers arise through the acquisition of oncogenic mutations and grow through clonal expansion1, 2. Here we reveal that most mutagenic DNA lesions are not resolved as mutations within a single cell-cycle. Instead, DNA lesions segregate unrepaired into daughter cells for multiple cell generations, resulting in the chromosome-scale phasing of subsequent mutations. We characterise this process in mutagen-induced mouse liver tumours and show that DNA replication across persisting lesions can generate multiple alternative alleles in successive cell divisions, thereby increasing both multi-allelic and combinatorial genetic diversity. The phasing of lesions enables the accurate measurement of strand biased repair processes, the quantification of oncogenic selection, and the fine mapping of sister chromatid exchange events. Finally, we demonstrate that lesion segregation is a unifying property of exogenous mutagens, including UV light and chemotherapy agents in human cells and tumours, which has profound implications for the evolution and adaptation of cancer genomes.

cancer biology↗

Mutational landscape of a chemically-induced mouse model of liver cancer

Carcinogen-induced mouse models of liver cancer are used extensively to study the pathogenesis of the disease and have a critical role in validating candidate therapeutics. These models can recapitulate molecular and histological features of human disease. However, it is not known if the spectra of genomic alterations driving these mouse tumour genomes are comparable to those found in humans. Here, we provide a detailed characterisation of the exome-wide pattern of mutations in tumours from mice exposed to diethylnitrosamine (DEN), a commonly used model of hepatocellular carcinoma (HCC). DEN-initiated tumours had a high, uniform number of somatic single nucleotide variants (SNVs), with very few insertions, deletions or copy number alterations, consistent with the known genotoxic action of DEN. Exposure of hepatocytes to DEN left a reproducible mutational imprint in resulting tumour exomes which we could computationally reconstruct using six known COSMIC mutational signatures. The tumours carried a high diversity of low-incidence, non-synonymous point mutations in many oncogenes and tumour suppressors, reflecting the stochastic introduction of SNVs into the hepatocyte genome by the carcinogen. We identified four recurrently mutated genes that were putative oncogenic drivers of HCC in this model. Every neoplasm carried activating hotspot mutations either in codon 61 of Hras, in codon 584 of Braf or in codon 254 of Egfr. Truncating mutations of Apc occurred in 21% of neoplasms, which were exclusively carcinomas supporting a role for deregulation of Wnt/{beta}-catenin signalling in cancer progression. Conclusion: Our study provides detailed insight into the mutational landscape of tumours arising in a commonly-used carcinogen model of hepatocellular carcinoma, facilitating the future use of this model to understand the human disease.

cancer biology↗